This brand name is authorized in Austria, Poland, Romania
The drug CYRDANAX contains one active pharmaceutical ingredient (API):
|
1
Dexrazoxane
UNII 5346058Q7S - DEXRAZOXANE HYDROCHLORIDE
|
|
Dexrazoxane has two major mechanisms of action, chelation of iron and inhibition of topoisomerase II. It is not known to what extent each of these mechanisms contributes to the preventive effect on tissue destruction following anthracycline extravasation. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V03AF02 | Dexrazoxane | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100281177 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W59811001, W59811002, W59811003, W59811004 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
